![1]()
News
Care via video teleconferencing can be as effective as in-person for some conditions
December 6, 2021
Video teleconferencing works best for monitoring patients with chronic conditions, according to the author of a new paper.
News
New virus causing ‘Alaskapox’ detected in two more cases
September 24, 2021
Sampling of the pox mark showed that it was caused by a previously unidentified virus of the same family as smallpox and cowpox.
News
Psoriasis associated with an increased risk of COVID-19 in real-world study
April 28, 2021
Those treated with TNF-alpha inhibitors, methotrexate, and apremilast had statistically lower risks of COVID-19 vs. those on topical therapy.
News
Blacks and Hispanics have higher inpatient use for mycosis fungoides
April 15, 2021
Findings reinforce need to maintain “higher index of suspicion” in these patients.
![1]()
News
Data about COVID-19-related skin manifestations in children continue to emerge
April 14, 2021
Of 50 hospitalized children infected with COVID-19, 18 (36%) fulfilled criteria for Multisystem Inflammatory Syndrome in Children.
![1]()
News
Are there COVID-19–related ‘long-haul’ skin issues?
January 28, 2021
Dr. Freeman believes that pernio and especially persistent lesions are caused by an immune response to COVID.
![1]()
News
COVID-19 vaccines: Safe for immunocompromised patients?
December 17, 2020
Data are limited thus far, and the safety and efficacy of the COVID-19 vaccines in immunocompromised patients remain unknown.
![1]()
News
What happened to melanoma care during COVID-19 sequestration
November 11, 2020
Preliminary evidence indicates delayed diagnosis and treatment measurably worsened outcome indicators.
News
Biologics may protect psoriasis patients against severe COVID-19
November 2, 2020
Preliminary evidence suggests biologics prevent the fearsome COVID-19 late cytokine storm.
News
COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
September 16, 2020
No increase was seen in hospitalization and death rates, providing additional support for keeping patients on these immunosuppressive treatments during the COVID-19 pandemic, although more research is needed and shared decision making is warranted.
